AZITHROMYCIN (azithromycin) by Entera Bio is drug. First approved in 2006.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
Azithromycin is a macrolide antibiotic available as an injectable formulation used to treat bacterial infections across multiple therapeutic areas. The drug works by inhibiting bacterial protein synthesis, making it effective against a broad spectrum of gram-positive and gram-negative organisms. It represents a mature, widely-used antimicrobial with established clinical utility.
With LOE approaching, the brand team is likely in a defensive posture focused on lifecycle management and cost optimization rather than growth initiatives.
drug. [see Microbiology ()]
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations
Azithromycin Before Induction
Worked on AZITHROMYCIN at Entera Bio? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Azithromycin offers stability in a mature, well-established product with predictable market dynamics, but limited growth opportunities. This role is best suited for professionals skilled in lifecycle management, cost containment, and generic competition preparation rather than innovation and market expansion.